ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer
Conference Call to be Held at
ImmunoGen requested the meeting to discuss the results of the Phase 3
FORWARD I trial and a potential path to registration for mirvetuximab
monotherapy. The agency advised that, because FORWARD I did not meet its
primary endpoint under the pre-specified statistical analysis plan, the
data generated assessing the secondary endpoints from the study could
not be used to support an application for accelerated approval.
“We are encouraged by the consistent signal of anti-tumor activity and
the favorable benefit-risk profile in patients with high FRα expression
in our Phase 3 FORWARD I trial,” said
“Our meeting with
As previously announced, ImmunoGen is conducting an operational review of the business with the objective of extending the Company’s cash runway.
CONFERENCE CALL INFORMATION
ImmunoGen will host a conference
call on
ABOUT FORWARD I
FORWARD I is a Phase 3 trial in which 366
patients were randomized 2:1 to receive either mirvetuximab soravtansine
or the physician's choice of single-agent chemotherapy (pegylated
liposomal doxorubicin, topotecan, or weekly paclitaxel). Eligible
patients were diagnosed with platinum-resistant ovarian cancer that
expresses medium or high levels of FRα and were treated with up to three
prior regimens. The primary endpoint of this study was progression free
survival (PFS), which was assessed in the entire study population and in
the subset of patients with high FRα expression. ImmunoGen estimates
that 12,000-14,000 patients per year in the U.S. meet these criteria,
with a comparable number in the major markets in
ImmunoGen partnered with the
ABOUT MIRVETUXIMAB SORAVTANSINE
Mirvetuximab soravtansine
(IMGN853) is the first folate receptor alpha (FRα)-targeting ADC. It
uses a humanized FRα-binding antibody to target the ADC specifically to
FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill
the targeted cancer cells.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation
of antibody-drug conjugates (ADCs) to improve outcomes for cancer
patients. By generating targeted therapies with enhanced anti-tumor
activity and favorable tolerability profiles, we aim to disrupt the
progression of cancer and offer our patients more good days. We call
this our commitment to “target a better now.” The Company has built a
productive platform generating a broad pipeline of ADCs targeting solid
tumors and hematologic malignancies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
FORWARD-LOOKING STATEMENTS
This press release includes
forward-looking statements based on management's current expectations.
These statements include, but are not limited to, ImmunoGen's
expectations related to: the occurrence, timing and outcome of potential
pre-clinical, clinical and regulatory events related to the Company's
and its collaboration partners' product programs; and the presentation
of preclinical and clinical data on the Company’s and collaboration
partners’ product candidates. For these statements, ImmunoGen claims the
protection of the safe harbor for forward-looking statements provided by
the Private Securities Litigation Reform Act of 1995. Various factors
could cause ImmunoGen's actual results to differ materially from those
discussed or implied in the forward-looking statements, and you are
cautioned not to place undue reliance on these forward-looking
statements, which are current only as of the date of this release.
Factors that could cause future results to differ materially from such
expectations include, but are not limited to: the timing and outcome of
ImmunoGen's and the Company's collaboration partners' research and
clinical development processes; the difficulties inherent in the
development of novel pharmaceuticals, including uncertainties as to the
timing, expense and results of preclinical studies, clinical trials and
regulatory processes; ImmunoGen's ability to financially support its
product programs; ImmunoGen's dependence on collaborative partners;
industry merger and acquisition activity; and other factors more fully
described in ImmunoGen’s Annual Report on Form 10-K for the year
ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005239/en/
Source:
INVESTOR RELATIONS CONTACT
Sarah Kiely
781-895-0600
sarah.kiely@immunogen.com
MEDIA CONTACT
Courtney O’Konek
781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com